Matthias Zaiss1, Jens Uhlig2, Mark-Oliver Zahn3, Thomas Decker4, Helmar C Lehmann5, Johanna Harde6, Cathrin Hogrefe7, Corinne Vannier8, Norbert Marschner9. 1. Practice for Interdisciplinary Oncology and Hematology, Freiburg im Breisgau, Germany. 2. Practice for Internal Medicine, Hematology and Oncology, Naunhof, Germany. 3. Outpatient Center for Oncology, MVZ Onkologische Kooperation Harz, Goslar, Germany. 4. Practice for Hematology and Oncology, Ravensburg, Germany. 5. Department of Neurology, University Hospital of Cologne, Köln, Germany. 6. Department of Data Management, Statistics and Medical Informatics, iOMEDICO, Freiburg im Breisgau, Germany. 7. Department of Clinical Operations, iOMEDICO, Freiburg im Breisgau, Germany. 8. Medical Department, iOMEDICO, Freiburg im Breisgau, Germany, corinne.vannier@iomedico.com. 9. Medical Department, iOMEDICO, Freiburg im Breisgau, Germany.
Abstract
INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect persisting after completion of neurotoxic chemotherapies. This observational study was designed to evaluate the effectiveness of the dietary supplement OnLife® (patented mixture of specific fatty acids and palmitoylethanolamide) in improving symptoms of CIPN in breast and colon cancer patients. METHODS: Improvement of CIPN was evaluated in adult patients, previously treated with (neo)adjuvant paclitaxel- (breast cancer) or oxaliplatin-based (colon cancer) therapies, receiving OnLife® for 3 months after completion of chemotherapy. The primary endpoint was to compare the severity of peripheral sensory neuropathy (PSN) and peripheral motor neuropathy (PMN) before and at the end of OnLife® treatment. Secondary endpoints included the assessment of patient-reported quality of life and CIPN symptoms as assessed by questionnaires. RESULTS: 146 patients (n = 75 breast cancer patients and n = 71 colon cancer patients) qualified for analysis; 31.1% and 37.5% of breast cancer patients had an improvement of PSN and PMN, respectively. In colon cancer patients, PSN and PMN improved in 16.9% and 20.0% of patients, respectively. According to patient-reported outcomes, 45.9% and 37.5% of patients with paclitaxel-induced PSN and PMN, and 23.9% and 22.0% of patients with oxaliplatin-induced PSN and PMN experienced a reduction of CIPN symptoms, respectively. CONCLUSION: OnLife® treatment confirmed to be beneficial in reducing CIPN severity and in limiting the progression of neuropathy, more markedly in paclitaxel-treated patients and also in patients with oxaliplatin-induced CIPN.
INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect persisting after completion of neurotoxic chemotherapies. This observational study was designed to evaluate the effectiveness of the dietary supplement OnLife® (patented mixture of specific fatty acids and palmitoylethanolamide) in improving symptoms of CIPN in breast and colon cancer patients. METHODS: Improvement of CIPN was evaluated in adult patients, previously treated with (neo)adjuvant paclitaxel- (breast cancer) or oxaliplatin-based (colon cancer) therapies, receiving OnLife® for 3 months after completion of chemotherapy. The primary endpoint was to compare the severity of peripheral sensory neuropathy (PSN) and peripheral motor neuropathy (PMN) before and at the end of OnLife® treatment. Secondary endpoints included the assessment of patient-reported quality of life and CIPN symptoms as assessed by questionnaires. RESULTS: 146 patients (n = 75 breast cancer patients and n = 71 colon cancer patients) qualified for analysis; 31.1% and 37.5% of breast cancer patients had an improvement of PSN and PMN, respectively. In colon cancer patients, PSN and PMN improved in 16.9% and 20.0% of patients, respectively. According to patient-reported outcomes, 45.9% and 37.5% of patients with paclitaxel-induced PSN and PMN, and 23.9% and 22.0% of patients with oxaliplatin-induced PSN and PMN experienced a reduction of CIPN symptoms, respectively. CONCLUSION: OnLife® treatment confirmed to be beneficial in reducing CIPN severity and in limiting the progression of neuropathy, more markedly in paclitaxel-treated patients and also in patients with oxaliplatin-induced CIPN.
Authors: Robson da Costa; Giselle F Passos; Nara L M Quintão; Elizabeth S Fernandes; João Raphael L C B Maia; Maria Martha Campos; João B Calixto Journal: Br J Pharmacol Date: 2020-06-03 Impact factor: 8.739
Authors: Charles L Loprinzi; Christina Lacchetti; Jonathan Bleeker; Guido Cavaletti; Cynthia Chauhan; Daniel L Hertz; Mark R Kelley; Antoinette Lavino; Maryam B Lustberg; Judith A Paice; Bryan P Schneider; Ellen M Lavoie Smith; Mary Lou Smith; Thomas J Smith; Nina Wagner-Johnston; Dawn L Hershman Journal: J Clin Oncol Date: 2020-07-14 Impact factor: 44.544
Authors: B Jordan; A Margulies; F Cardoso; G Cavaletti; H S Haugnes; P Jahn; E Le Rhun; M Preusser; F Scotté; M J B Taphoorn; K Jordan Journal: Ann Oncol Date: 2020-07-30 Impact factor: 32.976
Authors: A Truini; A Biasiotta; G Di Stefano; S La Cesa; C Leone; C Cartoni; V Federico; M T Petrucci; G Cruccu Journal: CNS Neurol Disord Drug Targets Date: 2011-12 Impact factor: 4.388
Authors: Susanna B Park; David Goldstein; Arun V Krishnan; Cindy S-Y Lin; Michael L Friedlander; James Cassidy; Martin Koltzenburg; Matthew C Kiernan Journal: CA Cancer J Clin Date: 2013 Nov-Dec Impact factor: 508.702
Authors: Ali Esfahani; Mohammad Hossein Somi; Hormoz Ayromlou; Alireza Nikanfar; Mohammad Asghari Jafarabadi; Bina Eftekhar Sadat; Zohreh Ghoreishi Journal: Biomark Res Date: 2016-06-23
Authors: Morgan Zhang; Min Hu; Sascha R A Alles; Marena A Montera; Ian Adams; Maria D Santi; Kenji Inoue; Nguyen Huu Tu; Karin N Westlund; Yi Ye Journal: Neuropharmacology Date: 2022-08-22 Impact factor: 5.273